Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea flag South Korea · Delayed Price · Currency is KRW
51,100
-4,900 (-8.75%)
At close: Dec 5, 2025

Hanall Biopharma Revenue

Hanall Biopharma had revenue of 40.80B KRW in the quarter ending September 30, 2025, with 10.76% growth. This brings the company's revenue in the last twelve months to 154.05B, up 14.76% year-over-year. In the year 2024, Hanall Biopharma had annual revenue of 138.94B with 2.99% growth.

Revenue (ttm)
154.05B
Revenue Growth
+14.76%
P/S Ratio
16.84
Revenue / Employee
506.75M
Employees
304
Market Cap
2,594.85B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024138.94B4.03B2.99%
Dec 31, 2023134.91B24.91B22.65%
Dec 31, 2022110.00B8.40B8.27%
Dec 31, 2021101.59B12.99B14.66%
Dec 31, 202088.60B-19.85B-18.30%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 5,504.84B
Celltrion 3,895.99B
ALTEOGEN 202.18B
ABL Bio 88.44B
SK Biopharmaceuticals 675.41B
Yuhan 2,136.67B
LigaChem Biosciences 159.27B
Peptron 6.19B
Revenue Rankings